Mesenchymal stem cell - derived extracellular vesicles modulate immune function in sepsis
-
By
-
Qinghe Meng
-
Yuanhui Song
-
Chunyan Wang
-
Adam Novak
-
Niitiggya Taneja
-
Zhen Ma
-
Alex Helkin
-
Robert N. Cooney
-
July 14, 2026
Clinical Scorecard: Extracellular Vesicles from Mesenchymal Stem Cells Influence Immune Responses in Sepsis
At a Glance
| Category | Detail |
|---|
| Condition | Sepsis |
| Key Mechanisms | Dysregulated immune responses, hyperinflammation, and immunosuppression. |
| Target Population | Patients with surgical sepsis meeting Sepsis-3 criteria. |
| Care Setting | Intensive care units (ICUs) |
Key Highlights
- Increased age, cancer diagnosis, and SOFA score associated with mortality.
- Non-survivors exhibited elevated IL-10 and MCP-1 levels.
- iMSC-EVs attenuated LPS-induced inflammation and apoptosis in PBMCs.
Guideline-Based Recommendations
Diagnosis
- Use Sepsis-3 criteria for diagnosing sepsis.
Management
- Consider iMSC-EVs as a therapeutic strategy for modulating immune responses.
Monitoring & Follow-up
- Monitor cytokine profiles, particularly IL-10 and TNF-α ratios.
Risks
- Elevated IL-10 levels and high IL-10/TNF-α ratios are associated with increased mortality.
Patient & Prescribing Data
Patients with surgical sepsis.
iMSC-EVs may restore immune homeostasis and reduce inflammation.
Clinical Best Practices
- Assess cytokine levels to evaluate immunosuppression severity.
- Utilize SOFA score for mortality risk assessment.
Related Resources & Content
